Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mol Cell Biochem ; 2023 Oct 03.
Artigo em Inglês | MEDLINE | ID: mdl-37787834

RESUMO

The use of nanoparticles (NPs) has emerged as a potential tool for safe and effective drug delivery. In the present study, we developed small molecule P7C3-based NPs and tested its efficacy and toxicity along with the tissue specific aptamer-modified P7C3 NPs. The P7C3 NPs were prepared using poly (D, L-lactic-co-glycolic acid) carboxylic acid (PLGA-COOH) polymer, were conjugated with skeletal muscle-specific RNA aptamer (A01B P7C3 NPs) and characterized for its cytotoxicity, cellular uptake, and wound healing in vitro. The A01B P7C3 NPs demonstrated an encapsulation efficiency of 30.2 ± 2.6%, with the particle size 255.9 ± 4.3 nm, polydispersity index of 0.335 ± 0.05 and zeta potential of + 10.4 ± 1.8mV. The FTIR spectrum of P7C3 NPs displayed complete encapsulation of the drug in the NPs. The P7C3 NPs and A01B P7C3 NPs displayed sustained drug release in vitro for up to 6 days and qPCR analysis confirmed A01B aptamer binding to P7C3 NPs. The C2C12 cells viability assay displayed no cytotoxic effects of all 3 formulations at 48 and 72 h. In addition, the cellular uptake of A01B P7C3 NPs in C2C12 myoblasts demonstrated higher uptake. In vitro assay mimicking wound healing showed improved wound closure with P7C3 NPs. In addition, P7C3 NPs significantly decreased TNF-α induced NF-κB activity in the C2C12/NF-κB reporter cells after 24-hour treatment. The P7C3 NPs showed 3-4-fold higher efficacy compared to P7C3 solutions in both wound-closure and inflammation assays in C2C12 cells. Furthermore, the P7C3 NPs showed 3-4-fold higher efficacy in reducing the infarct size and protected mouse hearts from ex vivo ischemia-reperfusion injury. Overall, this study demonstrates the safe and effective delivery of P7C3 NPs.

2.
J Pharmacol Exp Ther ; 382(2): 233-245, 2022 08.
Artigo em Inglês | MEDLINE | ID: mdl-35680376

RESUMO

Diabetes is associated with increased cardiac injury and sudden death. Nicotinamide phosphoribosyltransferase (Nampt) is an essential enzyme for the NAD+ salvage pathway and is dysregulated in diabetes. Nampt activation results in rescued NADH/NAD+ ratios and provides pharmacological changes necessary for diabetic cardioprotection. Computer docking shows that 1-(3,6-Dibromo-carbazol-9-yl)-3-phenylamino-propan-2-ol (P7C3) allows for enhanced Nampt dimerization and association. To test the pharmacological application, we used male leptin receptor-deficient (db/db) mice and treated them with Nampt activator P7C3. The effects of 4-week P7C3 treatment on cardiac function were evaluated along with molecular signaling changes for phosphorylated protein kinase B (p-AKT), phosphorylated endothelial nitric oxide synthase (p-eNOS), and sirtuin 1 (SIRT1). The cardiac function evaluated by ECG and echocardiography were significantly improved after 4 weeks of P7C3 treatment. Biochemically, higher NADH/NAD+ ratios in diabetic hearts were rescued by P7C3 treatment. Moreover, activities of Nampt and SIRT1 were significantly increased in P7C3-treated diabetic hearts. P7C3 treatment significantly decreased the blood glucose in diabetic mice with 4-week treatment as noted by glucose tolerance test and fasting blood glucose measurements compared with vehicle-treated mice. P7C3 activated Nampt enzymatic activity both in vitro and in the 4-week diabetic mouse hearts, demonstrating the specificity of the small molecule. P7C3 treatment significantly enhanced the expression of cardioprotective signaling of p-AKT, p-eNOS, and Beclin 1 in diabetic hearts. Nampt activator P7C3 allows for decreased infarct size with decreased Troponin I and lactose dehydrogenase (LDH) release, which is beneficial to the heart. Overall, the present study shows that P7C3 activates Nampt and SIRT1 activity and decreases NADH/NAD+ ratio, resulting in improved biochemical signaling providing cardioprotection. SIGNIFICANCE STATEMENT: This study shows that 1-(3,6-Dibromo-carbazol-9-yl)-3-phenylamino-propan-2-ol (P7C3) is effective in treating diabetes and cardiovascular diseases. The novel small molecule is antiarrhythmic and improves the ejection fraction in diabetic hearts. The study successfully demonstrated that P7C3 decreases the infarct size in hearts during myocardial infarction and ischemia-reperfusion injury. Biochemical and cellular signaling show increased NAD+ levels, along with Nampt activity involved in upregulating protective signaling in the diabetic heart. P7C3 has high therapeutic potential for rescuing heart disease.


Assuntos
Diabetes Mellitus Experimental , Infarto do Miocárdio , Animais , Glicemia , Carbazóis , Citocinas/metabolismo , Diabetes Mellitus Experimental/complicações , Diabetes Mellitus Experimental/tratamento farmacológico , Diabetes Mellitus Experimental/metabolismo , Masculino , Camundongos , Infarto do Miocárdio/tratamento farmacológico , NAD/metabolismo , Nicotinamida Fosforribosiltransferase , Proteínas Proto-Oncogênicas c-akt , Sirtuína 1/metabolismo
3.
J Cachexia Sarcopenia Muscle ; 13(2): 1177-1196, 2022 04.
Artigo em Inglês | MEDLINE | ID: mdl-35060352

RESUMO

BACKGROUND: Nicotinamide phosphoribosyltransferase (Nampt), a key enzyme in NAD salvage pathway is decreased in metabolic diseases, and its precise role in skeletal muscle function is not known. We tested the hypothesis, Nampt activation by P7C3 (3,6-dibromo-α-[(phenylamino)methyl]-9H-carbazol-9-ethanol) ameliorates diabetes and muscle function. METHODS: We assessed the functional, morphometric, biochemical, and molecular effects of P7C3 treatment in skeletal muscle of type 2 diabetic (db/db) mice. Nampt+/- mice were utilized to test the specificity of P7C3. RESULTS: Insulin resistance increased 1.6-fold in diabetic mice compared with wild-type mice and after 4 weeks treatment with P7C3 rescued diabetes (P < 0.05). In the db-P7C3 mice fasting blood glucose levels decreased to 0.96-fold compared with C57Bl/6J wild-type naïve control mice. The insulin and glucose tolerance tests blood glucose levels were decreased to 0.6-fold and 0.54-folds, respectively, at 120 min along with an increase in insulin secretion (1.76-fold) and pancreatic ß-cells (3.92-fold) in db-P7C3 mice. The fore-limb and hind-limb grip strengths were increased to 1.13-fold and 1.17-fold, respectively, together with a 14.2-fold increase in voluntary running wheel distance in db-P7C3 mice. P7C3 treatment resulted in a 1.4-fold and 7.1-fold increase in medium-sized and larger-sized myofibres cross-sectional area, with a concomitant 0.5-fold decrease in smaller-sized myofibres of tibialis anterior (TA) muscle. The transmission electron microscopy images also displayed a 1.67-fold increase in myofibre diameter of extensor digitorum longus muscle along with 2.9-fold decrease in mitochondrial area in db-P7C3 mice compared with db-Veh mice. The number of SDH positive myofibres were increased to 1.74-fold in db-P7C3 TA muscles. The gastrocnemius and TA muscles displayed a decrease in slow oxidative myosin heavy chain type1 (MyHC1) myofibres expression (0.46-fold) and immunostaining (6.4-fold), respectively. qPCR analysis displayed a 2.9-fold and 1.3-fold increase in Pdk4 and Cpt1, and 0.55-fold and 0.59-fold decrease in Fgf21 and 16S in db-P7C3 mice. There was also a 3.3-fold and 1.9-fold increase in Fabp1 and CD36 in db-Veh mice. RNA-seq differential gene expression volcano plot displayed 1415 genes to be up-regulated and 1726 genes down-regulated (P < 0.05) in db-P7C3 mice. There was 1.02-fold increase in serum HDL, and 0.9-fold decrease in low-density lipoprotein/very low-density lipoprotein ratio in db-P7C3 mice. Lipid profiling of gastrocnemius muscle displayed a decrease in inflammatory lipid mediators n-6; AA (0.83-fold), and n-3; DHA (0.69-fold) and EPA (0.81-fold), and a 0.66-fold decrease in endocannabinoid 2-AG and 2.0-fold increase in AEA in db-P7C3 mice. CONCLUSIONS: Overall, we demonstrate that P7C3 activates Nampt, improves type 2 diabetes and skeletal muscle function in db/db mice.


Assuntos
Carbazóis , Diabetes Mellitus Experimental , Diabetes Mellitus Tipo 2 , Animais , Carbazóis/farmacologia , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Tipo 2/tratamento farmacológico , Lipídeos , Camundongos , Músculo Esquelético , Nicotinamida Fosforribosiltransferase/genética , Nicotinamida Fosforribosiltransferase/metabolismo
4.
Mol Cell Biochem ; 436(1-2): 71-78, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28585087

RESUMO

We previously demonstrated the role of Kvß1.1 subunit of voltage-activated potassium channel in heart for its sensory roles in detecting changes in NADH/NAD and modulation of ion channel. However, the pharmacological role for the association of Kvß1 via its binding to ligands such as cortisone and its analogs remains unknown. Therefore, we investigated the significance of Kvß1.1 binding to cortisone analogs and AR inhibitor epalrestat. In addition, the aldose reductase (AR) inhibitor epalrestat was identified as a pharmacological target and modulator of cardiac activity via binding to the Kvß1 subunit. Using a combination of ex vivo cardiac electrophysiology and in silico binding, we identified that Kvß1 subunit binds and interacts with epalrestat. To identify the specificity of the action potential changes, we studied the sensitivity of the action potential prolongation by probing the electrical changes in the presence of 4-aminopyridine and evaluated the specificity of pharmacological effects in the hearts from Kvß1.1 knock out mouse. Our results show that pharmacological modulation of cardiac electrical activity by cortisone analogs and epalrestat is mediated by Kvß1.1.


Assuntos
Potenciais de Ação/efeitos dos fármacos , Aldeído Redutase/antagonistas & inibidores , Cortisona/farmacologia , Inibidores Enzimáticos/farmacologia , Canal de Potássio Kv1.1/metabolismo , Miocárdio/metabolismo , Rodanina/análogos & derivados , Tiazolidinas/farmacologia , Potenciais de Ação/genética , Animais , Canal de Potássio Kv1.1/genética , Camundongos , Camundongos Knockout , Rodanina/farmacologia
5.
Exp Physiol ; 101(4): 494-508, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-27038296

RESUMO

NEW FINDINGS: What is the central question of this study? The goal of this study was to evaluate sex differences and the role of the potassium channel ß1 (Kvß1) subunit in the heart. What is the main finding and its importance? Genetic ablation of Kvß1.1 in females led to cardiac hypertrophy characterized by increased heart size, prolonged monophasic action potentials, elevated blood pressure and increased myosin heavy chain α (MHCα) expression. In contrast, male mice showed only electrical changes. Kvß1.1 binds the MHCα isoform at the protein level, and small interfering RNA targeted knockdown of Kvß1.1 upregulated MHCα. Cardiovascular disease is the leading cause of death and debility in women in the USA, and cardiac arrhythmias are a major concern. Voltage-gated potassium (Kv) channels along with the binding partners; Kvß subunits are major regulators of the action potential (AP) shape and duration (APD). The regulation of Kv channels by the Kvß1 subunit is unknown in female hearts. In the present study, we hypothesized that the Kvß1 subunit is an important regulator of female cardiac physiology. To test this hypothesis, we ablated (knocked out; KO) the KCNAB1 isoform 1 (Kvß1.1) subunit in mice and evaluated cardiac function and electrical activity by using ECG, monophasic action potential recordings and echocardiography. Our results showed that the female Kvß1.1 KO mice developed cardiac hypertrophy, and the hearts were structurally different, with enlargement and increased area. The electrical derangements caused by Kvß1.1 KO in female mice included long QTc and QRS intervals along with increased APD (APD20-90% repolarization). The male Kvß1.1 KO mice did not develop cardiac hypertrophy, but they showed long QTc and prolonged APD. Molecular analysis showed that several genes that support cardiac hypertrophy were significantly altered in Kvß1.1 KO female hearts. In particular, myosin heavy chain α expression was significantly elevated in Kvß1.1 KO mouse heart. Using a small interfering RNA strategy, we identified that knockdown of Kvß1 increases myosin heavy chain α expression in H9C2 cells. Collectively, changes in molecular and cell signalling pathways clearly point towards a distinct electrical and structural remodelling consistent with cardiac hypertrophy in the Kvß1.1 KO female mice.


Assuntos
Cardiomegalia/metabolismo , Cardiomegalia/fisiopatologia , Coração/fisiopatologia , Hemodinâmica/fisiologia , Canais de Potássio de Abertura Dependente da Tensão da Membrana/metabolismo , Subunidades Proteicas/metabolismo , Potenciais de Ação/fisiologia , Animais , Arritmias Cardíacas/metabolismo , Arritmias Cardíacas/fisiopatologia , Linhagem Celular , Ecocardiografia/métodos , Feminino , Ativação do Canal Iônico/fisiologia , Masculino , Camundongos , Ratos
6.
Biomed Res Int ; 2015: 403291, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25954749

RESUMO

Pongamia pinnata (L.) Pierre has been used in traditional medicine for the treatment for diabetes and metabolic disorder. The aim of this study was to investigate the effect of petroleum ether extract of the stem bark of P. pinnata (known as PPSB-PEE) on cardiomyopathy in diabetic rats. Diabetes was induced in overnight fasted Sprague-Dawley rats by using injection of streptozotocin (55 mg/kg, i.p.). Nicotinamide (100 mg/kg, i.p.) was administered 20 min before administration of streptozotocin. Rats were divided into group I: nondiabetic, group II: diabetic control (tween 80, 2%; 10 mL/kg, p.o.) as vehicle, and group III: PPSB-PEE (100 mg/kg, p.o.). The blood glucose level, ECG, hemodynamic parameters, cardiotoxic and antioxidant biomarkers, and histology of heart were carried out after 4 months after STZ with nicotinamide injection. PPSB-PEE treatment improved the electrocardiographic, hemodynamic changes; LV contractile function; biological markers; oxidative stress parameters; and histological changes in STZ induced diabetic rats. PPSB-PEE (100 mg/kg, p.o.) decreased blood glucose level, improved electrocardiographic parameters (QRS, QT, and QTc intervals) and hemodynamic parameters (SBP, DBP, EDP, max dP/dt, contractility index, and heart rate), controlled levels of cardiac biomarkers (CK-MB, LDH, and AST), and improved oxidative stress (SOD, MDA, and GSH) in diabetic rats. PPSB-PEE is a promising remedy against cardiomyopathy in diabetic rats.


Assuntos
Antioxidantes/administração & dosagem , Cardiotônicos/administração & dosagem , Diabetes Mellitus Experimental/tratamento farmacológico , Extratos Vegetais/administração & dosagem , Animais , Antioxidantes/química , Glicemia , Cardiotônicos/química , Diabetes Mellitus Experimental/complicações , Diabetes Mellitus Experimental/patologia , Teste de Tolerância a Glucose , Humanos , Masculino , Millettia/química , Niacinamida/toxicidade , Estresse Oxidativo/efeitos dos fármacos , Extratos Vegetais/química , Ratos , Estreptozocina/toxicidade
7.
J Vector Borne Dis ; 52(1): 1-10, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25815861

RESUMO

Viral hemorrhagic fevers (VHFs) are major public health problems in the South-East Asia Regional (SEAR) countries. VHFs are a group of illnesses; that are caused by four families of viruses, viz. Arenaviridae, Bunyaviridae, Filoviridae and Flaviviridae. All VHFs have common features: they affect several organs and damage the blood vessels. These symptoms are often accompanied by hemorrhage. To understand pathogenesis, genetic and environmental influence that increase the risk of VHFs, efficacy and safety studies on candidate vaccines and testing of various therapeutic agents, appropriate animal models are essential tools in public and animals health. In the current review, the suitable animal models for Flavivirus [Dengue hemorhagic fever (DHF), Kyasanur forest disease (KFD)]; Bunyavirus [Crimean-Congo hemorrhagic fever (CCHF), Hantavirus fever (HF)]; and Paramyxovirus [Nipah virus fever (NiV)] have been reviewed with specific emphasis on emerging and reemerging viruses in SEAR countries.


Assuntos
Febres Hemorrágicas Virais/virologia , Modelos Animais , Vírus de RNA/fisiologia , Animais , Sudeste Asiático , Humanos , Saúde Pública
8.
PLoS One ; 9(3): e92697, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24651718

RESUMO

The objective of the present investigation was to evaluate the effect of L-glutamine on cardiac myopathy in streptozotocin-nicotinamide induced diabetic rats. Diabetes was induced in overnight fasted Sprague Dawely rats by using intraperitonial injection of streptozotocin (55 mg/kg). Nicotinamide (100 mg/kg, i.p.) was administered 20 min before administration of streptozotocin. Experimental rats were divided into Group I: non-diabetic control (distilled water; 10 ml/kg, p.o.), II: diabetic control (distilled water, 10 ml/kg, p.o.), III: L-glutamine (500 mg/kg, p.o.) and IV: L-glutamine (1000 mg/kg, p.o.). All groups were diabetic except group I. The plasma glucose level, body weight, electrocardiographic abnormalities, hemodynamic changes and left ventricular contractile function, biological markers of cardiotoxicity, antioxidant markers were determined after 4 months after STZ with nicotinamide injection. Histopathological changes of heart tissue were carried out by using H and E stain. L-glutamine treatment improved the electrocardiographic, hemodynamic changes; LV contractile function; biological markers; oxidative stress parameters and histological changes in STZ induced diabetic rats. Results from the present investigation demonstrated that L-glutamine has seemed a cardioprotective activity.


Assuntos
Diabetes Mellitus Experimental/metabolismo , Cardiomiopatias Diabéticas/metabolismo , Cardiomiopatias Diabéticas/prevenção & controle , Suplementos Nutricionais , Glutamina/metabolismo , Animais , Glicemia , Peso Corporal , Cardiotônicos/administração & dosagem , Cardiotônicos/metabolismo , Diabetes Mellitus Experimental/complicações , Cardiomiopatias Diabéticas/diagnóstico , Cardiomiopatias Diabéticas/etiologia , Modelos Animais de Doenças , Eletroencefalografia , Glutamina/administração & dosagem , Hemodinâmica , Masculino , Miocárdio/metabolismo , Miocárdio/patologia , Ratos
9.
PLoS One ; 8(8): e72817, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24023648

RESUMO

Previously we have reported that, cycloart-23-ene-3ß, 25-diol (called as B2) and L-glutamine stimulated glucagon like peptide-1 (GLP-1) (7-36) amide secretion diabetic rats. The objective of present investigation was to investigate the concomitant administration of cycloart-23-ene-3ß, 25-diol+sitagliptin and L-glutamine+sitagliptin in streptozotocin - nicotinamide induced diabetic Sprague Dawley. Type 2 diabetes was induced in overnight fasted male Sprague Dawley rats pre-treated with nicotinamide (100 mg/kg, i.p.) followed by administration of streptozotocin (55 mg/kg, i.p.) 20 min after. The rats were divided into; I- non-diabetic, II- diabetic control, III- Sitagliptin (5 mg/kg, p.o.)+cycloart-23-ene-3ß, 25-diol (1 mg/kg, p.o.), IV- Sitagliptin (5 mg/kg, p.o.)+L-glutamine (1000 mg/kg, p.o.). The concomitant treatment of cycloart-23-ene-3ß, 25-diol and L-glutamine with sitagliptin was 8 weeks. Plasma glucose, body weight, food and water intake were determined every week. Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress were measured after 8(th) week treatment. Concomitant administration of cycloart-23-ene-3ß, 25-diol and L-glutamine with sitagliptin significantly (p<0.001) reduced plasma glucose, glyoxylated haemoglobin, lipid profile and oxidative stress parameters compared to diabetic control groups. Both concomitant treatment increased plasma and pancreatic insulin as well as plasma and colonic active (GLP-1) (7-36) amide secretion. Histological analysis by Gomori staining observed less destruction of pancreatic ß cells. The result obtained from this study; it is concluded that concomitant administration of cycloart-23-ene-3ß, 25-diol+sitagliptin and L-glutamine+sitagliptin showed additive antihyperglycaemic effect in diabetic rats.


Assuntos
Diabetes Mellitus Experimental/tratamento farmacológico , Peptídeo 1 Semelhante ao Glucagon/metabolismo , Glutamina/farmacologia , Glutamina/uso terapêutico , Estresse Oxidativo/efeitos dos fármacos , Pirazinas/farmacologia , Triazóis/farmacologia , Triterpenos/farmacologia , Animais , Biomarcadores/metabolismo , Glicemia/metabolismo , Peso Corporal/efeitos dos fármacos , Colo/efeitos dos fármacos , Colo/metabolismo , Diabetes Mellitus Experimental/sangue , Comportamento de Ingestão de Líquido/efeitos dos fármacos , Comportamento Alimentar/efeitos dos fármacos , Peptídeo 1 Semelhante ao Glucagon/sangue , Glutamina/administração & dosagem , Hemoglobinas Glicadas/metabolismo , Insulina/sangue , Metabolismo dos Lipídeos/efeitos dos fármacos , Masculino , Niacinamida , Pâncreas/efeitos dos fármacos , Pâncreas/metabolismo , Pâncreas/patologia , Pirazinas/administração & dosagem , Pirazinas/uso terapêutico , Ratos , Ratos Sprague-Dawley , Fosfato de Sitagliptina , Coloração e Rotulagem , Estreptozocina , Triazóis/administração & dosagem , Triazóis/uso terapêutico , Triterpenos/administração & dosagem , Triterpenos/uso terapêutico
10.
Chem Biol Interact ; 203(2): 530-41, 2013 Apr 25.
Artigo em Inglês | MEDLINE | ID: mdl-23466488

RESUMO

L-glutamine is a non-essential amino acid. It decreased blood sugar, stimulated insulin secretion in type 2 diabetic patients. The objective of the present investigation was to evaluate L-glutamine increases glucagon like peptide-1 (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats. Molecular docking study was performed to elucidate the molecular basis for GLP-1 receptor agonistic activity. Type 2 diabetes was induced in overnight fasted Sprague Dawley rats pre-treated with nicotinamide (100 mg/kg, i.p.) followed by 20 min after administration of streptozotocin (55 mg/kg, i.p.). The rats were divided into; I - nondiabetic, II - diabetic control, III - sitagliptin (5 mg/kg, p.o.), IV - L-glutamine (250 mg/kg, p.o.), V - L-glutamine (500 mg/kg, p.o.) and VI - L-glutamine (1000 mg/kg, p.o.). The L-glutamine and sitagliptin treatment was 8 week. Plasma glucose was estimated every week. Body weight, food and water intake were recorded daily. Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8 week. In acute study, the rats were divided into I - glucose (2.5 g/kg, p.o.), II - sitagliptin (5 mg/kg, p.o.), III - L-glutamine (250 mg/kg, p.o.), IV - L-glutamine (500 mg/kg, p.o.) and V - L-glutamine (1000 mg/kg, p.o.). Plasma glucose, active GLP-1 (7-36) amide concentration and insulin levels were measured after glucose loading. The docking data indicated that l-glutamine bind to the GLP-1 receptor. L-glutamine decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.


Assuntos
Glicemia/metabolismo , Diabetes Mellitus Experimental/sangue , Diabetes Mellitus Experimental/metabolismo , Peptídeo 1 Semelhante ao Glucagon/metabolismo , Glutamina/administração & dosagem , Glutamina/farmacologia , Niacinamida/efeitos adversos , Fragmentos de Peptídeos/metabolismo , Administração Oral , Animais , Peso Corporal/efeitos dos fármacos , Colo/efeitos dos fármacos , Colo/metabolismo , Diabetes Mellitus Experimental/fisiopatologia , Ingestão de Líquidos/efeitos dos fármacos , Regulação da Expressão Gênica/efeitos dos fármacos , Peptídeo 1 Semelhante ao Glucagon/sangue , Peptídeo 1 Semelhante ao Glucagon/genética , Receptor do Peptídeo Semelhante ao Glucagon 1 , Teste de Tolerância a Glucose , Glutamina/metabolismo , Hemoglobinas Glicadas/metabolismo , Insulina/sangue , Insulina/metabolismo , Metabolismo dos Lipídeos/efeitos dos fármacos , Masculino , Simulação de Acoplamento Molecular , Estresse Oxidativo/efeitos dos fármacos , Pâncreas/efeitos dos fármacos , Pâncreas/metabolismo , Pâncreas/patologia , Fragmentos de Peptídeos/sangue , Fragmentos de Peptídeos/genética , Conformação Proteica , Pirazinas/administração & dosagem , Pirazinas/metabolismo , Pirazinas/farmacologia , Ratos , Ratos Sprague-Dawley , Receptores de Glucagon/química , Receptores de Glucagon/metabolismo , Fosfato de Sitagliptina , Triazóis/administração & dosagem , Triazóis/metabolismo , Triazóis/farmacologia
11.
Eur J Pharmacol ; 698(1-3): 470-9, 2013 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-23117087

RESUMO

In previous study, we have reported cycloart-23-ene-3ß, 25-diol is an active antidiabetic constituent isolated from stem bark of Pongamia pinnata (Linn.) Pierre. The objective of the present investigation was to evaluate cycloart-23-ene-3ß, 25-diol stimulates glucagon like peptide-1 (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide induced diabetic Sprague Dawley rats. Molecular docking studies were performed to elucidate the molecular basis for GLP-1 receptor agonistic activity. Type 2 diabetes was induced in overnight fasted Sprague Dawley rats pre-treated with nicotinamide (100mg/kg, i.p.) followed by administration of streptozotocin (55 mg/kg, i.p.) 20 min after. The rats were divided into following groups; I- non-diabetic, II- diabetic control, III- sitagliptin (5mg/kg, p.o.), IV- cycloart-23-ene-3ß, 25-diol (1mg/kg, p.o.). The cycloart-23-ene-3ß, 25-diol and sitagliptin treatment was 8 week. Plasma glucose was estimated every week (week 0 to week 8). Body weight, food and water intake were recorded daily. Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagnon GLP-1, plasma and pancreatic insulin, histology of pancreata as well as biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8th week treatment. In acute study, active GLP-1 (7-36) amide release, plasma glucose and insulin were measured during oral glucose tolerance test. The docking data clearly indicated cycloart-23-ene-3ß, 25-diol bind to the GLP-1 receptor. It decreased plasma glucose level, increased plasma and pancreatic insulin level as well as increased plasma and colonic active GLP-1 (7-36) amide secretion in streptozotocin-nicotinamide induced diabetic Sprague Dawley rats.


Assuntos
Diabetes Mellitus Experimental/tratamento farmacológico , Peptídeo 1 Semelhante ao Glucagon/metabolismo , Niacinamida/efeitos adversos , Fragmentos de Peptídeos/metabolismo , Triterpenos/farmacologia , Animais , Biomarcadores/metabolismo , Glicemia/metabolismo , Peso Corporal/efeitos dos fármacos , Diabetes Mellitus Experimental/sangue , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/fisiopatologia , Ingestão de Líquidos/efeitos dos fármacos , Regulação da Expressão Gênica/efeitos dos fármacos , Peptídeo 1 Semelhante ao Glucagon/agonistas , Peptídeo 1 Semelhante ao Glucagon/química , Teste de Tolerância a Glucose , Insulina/sangue , Insulina/metabolismo , Masculino , Simulação de Acoplamento Molecular , Estresse Oxidativo/efeitos dos fármacos , Pâncreas/efeitos dos fármacos , Pâncreas/metabolismo , Fragmentos de Peptídeos/agonistas , Fragmentos de Peptídeos/química , Conformação Proteica , Pirazinas/administração & dosagem , Pirazinas/metabolismo , Pirazinas/farmacologia , Pirazinas/uso terapêutico , Ratos , Ratos Sprague-Dawley , Fosfato de Sitagliptina , Fatores de Tempo , Triazóis/administração & dosagem , Triazóis/metabolismo , Triazóis/farmacologia , Triazóis/uso terapêutico , Triterpenos/administração & dosagem , Triterpenos/metabolismo , Triterpenos/uso terapêutico
12.
Asian Pac J Trop Biomed ; 2(5): 337-44, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-23569927

RESUMO

OBJECTIVE: To elucidate the ameliorative effect of hydroalcoholic extract of leaves of Hibiscus rosa sinensis (HRS) in acetic acid induced experimental colitis in male wistar rats. METHODS: The animals were administered with 2 mL acetic acid (4%) via intra rectal. The animals were divided into various treatment groups (n=6). Prednisolone was used as standard drug and HRS was administered at a dose of 50, 100 and 200 mg/kg p.o. The control group of animals received 1 mL of vehicle (distilled water). Ulcer area, ulcer index, spleen weight, colon weight to length ratio, macroscopic score, haematological parameters, colonic superoxide dismutase (SOD), glutathione (GSH), myeloperoxidase (MPO), malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), nitric oxide (NO) and histological changes were recorded after the treatment regimen of 11 days. RESULTS: Intrarectal instillation of acetic acid caused enhanced ulcer area, ulcer index, spleen weight, colon weight to length ratio, colonic MPO, MDA, NO and TNF-α It caused significant decreased level of SOD and GSH. Pretreatment with HRS for 7 days exhibited significant effect in lowering of oxidative stress, colonic NO, TNF-α and elevation of SOD and GSH at a dose of 100 and 200 mg/kg in acetic acid induced colitis. CONCLUSIONS: The present investigation demonstrates HRS is of potent therapeutic value in the amelioration of experimental colitis in laboratory animals by inhibiting the proinflammatory mediator like NO and TNF-α.


Assuntos
Colite/patologia , Colo/patologia , Hibiscus/química , Fitoterapia/métodos , Folhas de Planta/química , Preparações de Plantas/farmacologia , Ácido Acético/toxicidade , Animais , Colite/tratamento farmacológico , Modelos Animais de Doenças , Glutationa , Masculino , Malondialdeído , Óxido Nítrico , Tamanho do Órgão , Estresse Oxidativo , Peroxidase , Ratos , Ratos Wistar , Superóxido Dismutase , Fator de Necrose Tumoral alfa
13.
Asian Pac J Trop Med ; 4(11): 910-6, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22078955

RESUMO

OBJECTIVE: To evaluate the in-vitro antioxidant and antimicrobial activity of cycloart-23-ene-3ß, 25-diol (called as B2) isolated from stem bark of Pongamia pinnata. METHODS: In vitro antioxidant activity of B2 was determined by methods for determination of DPPH radical scavenging, reducing power, superoxide anion radical scavenging, hydroxyl radical scavenging, hydrogen peroxide scavenging, metal chelating and nitric oxide radical scavenging at the doses of 20, 40, 60, 80 and 100 µg/mL, respectively. ß-tocopherol with same concentration was used as a standard antioxidant. In vitro antimicrobial activity of B2 was determined by cup plate method in different concentration range of 10-100 µg/mL. RESULTS: The results indicated that dose dependent % reduction against DPPH radical, reducing power, superoxide anion radical scavenging, hydroxyl radical scavenging, metal chelating, hydrogen peroxide scavenging and nitric oxide radical scavenging by B2 and ß-tocopherol. CONCLUSIONS: It is concluded that cycloart 23-ene-3ß, 25 diol (B2) showed dose dependent antioxidant activity. B2 showed more DPPH radical scavenging, reducing power, superoxide scavenging, hydroxyl radical scavenging, metal chelating scavenging, hydrogen peroxide radical scavenging and nitric oxide radical scavenging activity than ß-tocopherol and in case of antimicrobial activity B2 exhibited broad-spectrum activity against bacteria and strong activity against yeast type of fungi.


Assuntos
Millettia/química , Casca de Planta/química , Extratos Vegetais/farmacologia , Triterpenos/farmacologia , Relação Dose-Resposta a Droga , Compostos Ferrosos/metabolismo , Sequestradores de Radicais Livres/isolamento & purificação , Sequestradores de Radicais Livres/farmacologia , Humanos , Peróxido de Hidrogênio/metabolismo , Radical Hidroxila/metabolismo , Óxido Nítrico/metabolismo , Extratos Vegetais/isolamento & purificação , Superóxidos/metabolismo , Triterpenos/isolamento & purificação
14.
Pharm Biol ; 49(2): 182-9, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21043992

RESUMO

CONTEXT: Macrotyloma uniflorum (Lam.) Verdc. (Leguminosae) seeds, known as the poor man's pulse crop in India, have been used as a food and also used in the traditional method for treatment of kidney stones, diabetes, obesity, etc. OBJECTIVE: To investigate the antidiabetic effect of α-amylase inhibitor isolated from the seeds of Macrotyloma uniflorum seeds in streptozotocin-nicotinamide induced diabetic mice. MATERIALS AND METHOD: α-Amylase inhibitor was purified using a carboxymethyl cellulose (CMC) column. Kinetic studies were done using mouse pancreatic and human salivary α-amylase. Its antidiabetic effect was studied in streptozotocin-nicotinamide-induced diabetic mice. Biochemical parameters such as serum total cholesterol, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were determined. Histopathological investigation was performed on the pancreas, kidney, and liver tissue samples. RESULTS: Macrotyloma uniflorum α-amylase inhibitor (MUAI) inhibited both the mouse pancreatic and human salivary α-amylase in a non-competitive manner with K(i) values of 11 and 8.8 µM and IC(50) value of 30 and 12.5 µg/mL, respectively. It decreased the serum glucose level in the treated diabetic mice. Histological findings suggested minimum pathological changes in the treated diabetic mice as compared to the diabetic control. DISCUSSION AND CONCLUSION: The results suggest that MUAI has an antihyperglycemic activity and therefore can be used in the dietary treatment of non-insulin dependent diabetes mellitus.


Assuntos
Diabetes Mellitus Experimental/tratamento farmacológico , Fabaceae/química , alfa-Amilases Pancreáticas/antagonistas & inibidores , alfa-Amilases Salivares/antagonistas & inibidores , Animais , Glicemia/efeitos dos fármacos , Diabetes Mellitus Experimental/fisiopatologia , Diabetes Mellitus Tipo 2/tratamento farmacológico , Diabetes Mellitus Tipo 2/fisiopatologia , Inibidores Enzimáticos/isolamento & purificação , Inibidores Enzimáticos/farmacologia , Humanos , Hipoglicemiantes/isolamento & purificação , Hipoglicemiantes/farmacologia , Concentração Inibidora 50 , Masculino , Camundongos , Niacinamida , alfa-Amilases Pancreáticas/metabolismo , alfa-Amilases Salivares/metabolismo , Sementes , Estreptozocina
15.
Eur J Pharmacol ; 632(1-3): 103-9, 2010 Apr 25.
Artigo em Inglês | MEDLINE | ID: mdl-20122920

RESUMO

The aim of the present investigation was to evaluate the antidiabetic activity of cycloart-23-ene-3beta, 25-diol (called as B2) isolated from stem bark of Pongamia pinnata in streptozotocin-nicotinamide induced diabetic mice. Diabetes was induced in mice by injecting streptozotocin (200mg/kg, i.p.) after 15 min nicotinamide (110 mg/kg, i.p.). The mice were divided into following groups; I - nondiabeteic, II - diabetic control, III - glybenclamide (10mg/kg, p.o.), IV - B2 (1mg/kg, p.o.) and V - B2 (3mg/kg, p.o., only for acute study). Serum glucose was determined periodically. Body weight, food and water intake were recorded daily. Oral glucose tolerance test was performed on day 28. Biochemical and enzyme antioxidant parameters were determined. Histology of pancreas was performed. B2 and glybenclamide treatment reduced serum glucose in acute study. However in chronic study, increase in body weight and decrease in food and water intake was observed. Increased glucose utilization was observed in oral glucose tolerance test. Both glybenclamide and B2 increased serum and pancreatic insulin. Glycosylated haemoglobin, serum cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, globulin, bilirubin, lactate dehydrogenase, urea and uric acid were decreased significantly after B2 treatment. B2 treatment decreased liver malondialdehyde but increased superoxidase dismutase and reduced glutathione. Histologically, focal necrosis was observed in the diabetic mouse pancreata but was less obvious in treated groups. The mechanism of B2 appears to be due to increased pancreatic insulin secretion and antioxidant activity.


Assuntos
Diabetes Mellitus Experimental/tratamento farmacológico , Hipoglicemiantes/farmacologia , Hipoglicemiantes/uso terapêutico , Millettia/química , Triterpenos/farmacologia , Animais , Diabetes Mellitus Experimental/sangue , Teste de Tolerância a Glucose , Glibureto/uso terapêutico , Hipoglicemiantes/química , Hipoglicemiantes/isolamento & purificação , Camundongos , Modelos Químicos , Niacinamida/toxicidade , Estreptozocina/toxicidade , Triterpenos/química , Triterpenos/isolamento & purificação
16.
J Ethnopharmacol ; 123(1): 115-20, 2009 May 04.
Artigo em Inglês | MEDLINE | ID: mdl-19429349

RESUMO

AIM OF THE STUDY: The aim of the study was to evaluate the antihyperglycaemic activity of aqueous (PPSB-AQE) and petroleum ether (PPSB-PEE) extract of stem bark Pongamia pinnata in alloxan induced diabetic mice. MATERIALS AND METHODS: Diabetes was induced in mice by alloxan (80 mg/kg, i.v.). After acute and subacute treatment serum glucose was determined. OGTT was performed in PPSB-PEE pretreated animals. RESULTS: PPSB-PEE (25, 50, 100, 200 and 400mg/kg) showed significant reduction in serum glucose level in acute and subacute studies. The antihyperglycaemic effects of PPSBPE (100, 200 and 400mg/kg) showed onset at 2h and peak effect at 6h and the effect was sustained until 24 th h with 400mg/kg. In subacute study, antihyperglycaemic effect was observed on 21st day. In PPSBPE treated mice the body weight was not reduced in contrast to that in vehicle group. In OGTT, increased glucose utilization was observed. CONCLUSIONS: It is concluded that PPSB-PEE but not PPSB-AQE showed antihyperglycaemic activity.


Assuntos
Alcanos/química , Glicemia/análise , Diabetes Mellitus Experimental/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Millettia/química , Casca de Planta/química , Extratos Vegetais/uso terapêutico , Aloxano , Animais , Peso Corporal/efeitos dos fármacos , Diabetes Mellitus Experimental/sangue , Relação Dose-Resposta a Droga , Feminino , Teste de Tolerância a Glucose , Hipoglicemiantes/farmacologia , Masculino , Camundongos , Extratos Vegetais/farmacologia
17.
J Pharm Pharmacol ; 61(3): 387-93, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19222913

RESUMO

OBJECTIVES: The objective of this study was to evaluate the acute and chronic diuretic effect of the ethanolic extract of the leaves of Cocculus hirsutus (L.) Diles. METHODS: The ethanolic extract was administered (100, 200 and 400 mg/kg, p.o.) in Wistar rats. In the acute study, rats received drugs orally and urine was collected after 1, 2, 3, 4, 5 and 6 h. The chronic study involved repeated administration of ethanolic extract for 28 days and urine was collected on day 1, 7, 14, 21 and 28. The parameters were total urine volume, concentration of Na+, K+ and Cl- ions, creatinine in urine and serum. Urine output, electrolytes (Na+, K+ and Cl- ions) and creatinine were determined on day 7, 14, 21 and 28. KEY FINDINGS: The highest dose (400 mg/kg) of the ethanolic extract significantly (P < 0.01) enhanced urine output. Excretion of cations (Na+ and K+ ions) and anions (Cl- ions) increased significantly with respect to the control (gum acacia 2% dissolved in saline, 10 ml/kg) group. The increase of cations in the urine after treatment with ethanolic extract was dose dependent. The ethanolic extract of the leaves of C. hirsutus (100, 200 and 400 mg/kg) and furosemide (10 mg/kg) did not significantly change the concentration of Na+, K+ and Cl- ions in serum. The ethanolic extract of the leaves of C. hirsutus (100, 200 and 400 mg/kg) and furosemide (10 mg/kg) increased the excretion of creatinine in urine but with a corresponding decrease in serum. CONCLUSIONS: It was concluded that the ethanolic extract of the leaves of C. hirsutus (400 mg/kg) had significant diuretic effect in rats.


Assuntos
Cocculus/química , Diuréticos/farmacologia , Extratos Vegetais/farmacologia , Administração Oral , Animais , Cloretos/sangue , Cloretos/urina , Diuréticos/administração & dosagem , Diuréticos/toxicidade , Relação Dose-Resposta a Droga , Esquema de Medicação , Furosemida/farmacologia , Masculino , Extratos Vegetais/administração & dosagem , Extratos Vegetais/toxicidade , Folhas de Planta , Potássio/sangue , Potássio/urina , Ratos , Ratos Wistar , Sódio/sangue , Sódio/urina , Testes de Toxicidade Aguda
18.
Evid Based Complement Alternat Med ; 5(2): 159-64, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18604261

RESUMO

Mushrooms are low calorie food with very little fat and are highly suitable for obese persons. With no starch and very low sugars, they are the 'delight of the diabetics'. Combination of herbal drugs (or isolated phytochemicals) is found to be beneficial in certain diseases when given along with conventional drugs. The aim of the present study was to evaluate the effects of aqueous extract of Pleurotus pulmonarius (Lentinaceae) (called as PP-aqu) and its interaction with glyburide in alloxan induced diabetic mice. The diabetic mice treated were with PP-aqu (500 mg/kg, p.o.) alone or combination with glyburide (10 mg/kg, p.o.) for 28 days. Blood samples were collected by orbital sinus puncture using heparinized capillary glass tubes and were analyzed for serum glucose on 0, 7th, 14th, 21st and 28th days. Body weights and mortality were noted during the study period. In oral glucose tolerance test (OGTT), glucose (2.5 g/kg, p.o.) was administered with either vehicle, PP-aqu alone or in combination with glyburide and serum glucose level analyzed at 0, 30, 60 and 120 min after drug administration. Administration of PP-aqu (500 mg/kg) and its combination with glyburide (10 mg/kg) significantly (P < 0.001) decreased serum glucose level in diabetic mice. In OGTT, glyburide or PP-aqu treatment alone or their combination produced significant (P < 0.001) increase in glucose threshold. Thus we suggest that P. pulmonarius showed potent and synergistic antihyperglycemic effect in combination with glyburide.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...